PMC:7358770 / 20472-20798 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T35","span":{"begin":25,"end":36},"obj":"https://glytoucan.org/Structures/Glycans/G43702JT"}],"text":"For example, fucosylated chondroitin sulfate was effective in blocking laboratory strain HIV-1IIIB entry and replication (4.26 μg/mL and 0.73 μg/mL, respectively), and inhibiting infection by clinic isolate HIV-1KM018 and HIV-1TC-2 (23.75 μg/mL and 31.86 μg/mL, respectively) as well as suppressing HIV-1 drug-resistant virus."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T209","span":{"begin":25,"end":44},"obj":"Body_part"},{"id":"T210","span":{"begin":89,"end":92},"obj":"Body_part"},{"id":"T211","span":{"begin":207,"end":210},"obj":"Body_part"},{"id":"T212","span":{"begin":222,"end":225},"obj":"Body_part"},{"id":"T213","span":{"begin":299,"end":302},"obj":"Body_part"}],"attributes":[{"id":"A209","pred":"fma_id","subj":"T209","obj":"http://purl.org/sig/ont/fma/fma82837"},{"id":"A210","pred":"fma_id","subj":"T210","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A211","pred":"fma_id","subj":"T211","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A212","pred":"fma_id","subj":"T212","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A213","pred":"fma_id","subj":"T213","obj":"http://purl.org/sig/ont/fma/fma278683"}],"text":"For example, fucosylated chondroitin sulfate was effective in blocking laboratory strain HIV-1IIIB entry and replication (4.26 μg/mL and 0.73 μg/mL, respectively), and inhibiting infection by clinic isolate HIV-1KM018 and HIV-1TC-2 (23.75 μg/mL and 31.86 μg/mL, respectively) as well as suppressing HIV-1 drug-resistant virus."}

{"project":"LitCovid-PubTator","denotations":[{"id":"734","span":{"begin":89,"end":94},"obj":"Species"},{"id":"735","span":{"begin":207,"end":212},"obj":"Species"},{"id":"736","span":{"begin":222,"end":227},"obj":"Species"},{"id":"737","span":{"begin":299,"end":304},"obj":"Species"},{"id":"748","span":{"begin":25,"end":44},"obj":"Chemical"},{"id":"756","span":{"begin":179,"end":188},"obj":"Disease"}],"attributes":[{"id":"A734","pred":"tao:has_database_id","subj":"734","obj":"Tax:11676"},{"id":"A735","pred":"tao:has_database_id","subj":"735","obj":"Tax:11676"},{"id":"A736","pred":"tao:has_database_id","subj":"736","obj":"Tax:11676"},{"id":"A737","pred":"tao:has_database_id","subj":"737","obj":"Tax:11676"},{"id":"A748","pred":"tao:has_database_id","subj":"748","obj":"MESH:D002809"},{"id":"A756","pred":"tao:has_database_id","subj":"756","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"For example, fucosylated chondroitin sulfate was effective in blocking laboratory strain HIV-1IIIB entry and replication (4.26 μg/mL and 0.73 μg/mL, respectively), and inhibiting infection by clinic isolate HIV-1KM018 and HIV-1TC-2 (23.75 μg/mL and 31.86 μg/mL, respectively) as well as suppressing HIV-1 drug-resistant virus."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T89","span":{"begin":179,"end":188},"obj":"Disease"}],"attributes":[{"id":"A89","pred":"mondo_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"For example, fucosylated chondroitin sulfate was effective in blocking laboratory strain HIV-1IIIB entry and replication (4.26 μg/mL and 0.73 μg/mL, respectively), and inhibiting infection by clinic isolate HIV-1KM018 and HIV-1TC-2 (23.75 μg/mL and 31.86 μg/mL, respectively) as well as suppressing HIV-1 drug-resistant virus."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T213","span":{"begin":320,"end":325},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"For example, fucosylated chondroitin sulfate was effective in blocking laboratory strain HIV-1IIIB entry and replication (4.26 μg/mL and 0.73 μg/mL, respectively), and inhibiting infection by clinic isolate HIV-1KM018 and HIV-1TC-2 (23.75 μg/mL and 31.86 μg/mL, respectively) as well as suppressing HIV-1 drug-resistant virus."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T324","span":{"begin":25,"end":44},"obj":"Chemical"},{"id":"T325","span":{"begin":37,"end":44},"obj":"Chemical"},{"id":"T326","span":{"begin":305,"end":309},"obj":"Chemical"}],"attributes":[{"id":"A324","pred":"chebi_id","subj":"T324","obj":"http://purl.obolibrary.org/obo/CHEBI_37397"},{"id":"A325","pred":"chebi_id","subj":"T325","obj":"http://purl.obolibrary.org/obo/CHEBI_16189"},{"id":"A326","pred":"chebi_id","subj":"T326","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"For example, fucosylated chondroitin sulfate was effective in blocking laboratory strain HIV-1IIIB entry and replication (4.26 μg/mL and 0.73 μg/mL, respectively), and inhibiting infection by clinic isolate HIV-1KM018 and HIV-1TC-2 (23.75 μg/mL and 31.86 μg/mL, respectively) as well as suppressing HIV-1 drug-resistant virus."}

{"project":"LitCovid-sentences","denotations":[{"id":"T127","span":{"begin":0,"end":326},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"For example, fucosylated chondroitin sulfate was effective in blocking laboratory strain HIV-1IIIB entry and replication (4.26 μg/mL and 0.73 μg/mL, respectively), and inhibiting infection by clinic isolate HIV-1KM018 and HIV-1TC-2 (23.75 μg/mL and 31.86 μg/mL, respectively) as well as suppressing HIV-1 drug-resistant virus."}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T13","span":{"begin":25,"end":36},"obj":"GlycoEpitope"}],"attributes":[{"id":"A13","pred":"glyco_epitope_db_id","subj":"T13","obj":"http://www.glycoepitope.jp/epitopes/EP0081"}],"text":"For example, fucosylated chondroitin sulfate was effective in blocking laboratory strain HIV-1IIIB entry and replication (4.26 μg/mL and 0.73 μg/mL, respectively), and inhibiting infection by clinic isolate HIV-1KM018 and HIV-1TC-2 (23.75 μg/mL and 31.86 μg/mL, respectively) as well as suppressing HIV-1 drug-resistant virus."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T568","span":{"begin":25,"end":44},"obj":"CHEBI:37397;CHEBI:37397"},{"id":"T569","span":{"begin":109,"end":120},"obj":"GO:0006260"},{"id":"T570","span":{"begin":305,"end":309},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T571","span":{"begin":320,"end":325},"obj":"NCBITaxon:10239"},{"id":"T75769","span":{"begin":19,"end":31},"obj":"GO:0065003"},{"id":"T36200","span":{"begin":32,"end":40},"obj":"GO:0032993"},{"id":"T9017","span":{"begin":40,"end":47},"obj":"GO:0032993;CHEBI:60027;CHEBI:60027"},{"id":"T57402","span":{"begin":48,"end":57},"obj":"GO:0032993"},{"id":"T93024","span":{"begin":141,"end":146},"obj":"NCBITaxon:10239"},{"id":"T21478","span":{"begin":153,"end":164},"obj":"CHEBI:3435;CHEBI:3435"},{"id":"T46102","span":{"begin":213,"end":221},"obj":"GO:0035376"},{"id":"T75735","span":{"begin":222,"end":229},"obj":"GO:0035376;GO:0019012"},{"id":"T5160","span":{"begin":252,"end":263},"obj":"CHEBI:37168;CHEBI:37168"},{"id":"T92848","span":{"begin":289,"end":297},"obj":"CHEBI:34674;CHEBI:34674"},{"id":"T8418","span":{"begin":298,"end":312},"obj":"CHEBI:18154;CHEBI:18154"}],"text":"For example, fucosylated chondroitin sulfate was effective in blocking laboratory strain HIV-1IIIB entry and replication (4.26 μg/mL and 0.73 μg/mL, respectively), and inhibiting infection by clinic isolate HIV-1KM018 and HIV-1TC-2 (23.75 μg/mL and 31.86 μg/mL, respectively) as well as suppressing HIV-1 drug-resistant virus."}

{"project":"MyTest","denotations":[{"id":"734","span":{"begin":89,"end":94},"obj":"Species"},{"id":"735","span":{"begin":207,"end":212},"obj":"Species"},{"id":"736","span":{"begin":222,"end":227},"obj":"Species"},{"id":"737","span":{"begin":299,"end":304},"obj":"Species"},{"id":"748","span":{"begin":25,"end":44},"obj":"Chemical"},{"id":"756","span":{"begin":179,"end":188},"obj":"Disease"}],"attributes":[{"id":"A734","pred":"tao:has_database_id","subj":"734","obj":"Tax:11676"},{"id":"A735","pred":"tao:has_database_id","subj":"735","obj":"Tax:11676"},{"id":"A736","pred":"tao:has_database_id","subj":"736","obj":"Tax:11676"},{"id":"A737","pred":"tao:has_database_id","subj":"737","obj":"Tax:11676"},{"id":"A748","pred":"tao:has_database_id","subj":"748","obj":"MESH:D002809"},{"id":"A756","pred":"tao:has_database_id","subj":"756","obj":"MESH:D007239"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"For example, fucosylated chondroitin sulfate was effective in blocking laboratory strain HIV-1IIIB entry and replication (4.26 μg/mL and 0.73 μg/mL, respectively), and inhibiting infection by clinic isolate HIV-1KM018 and HIV-1TC-2 (23.75 μg/mL and 31.86 μg/mL, respectively) as well as suppressing HIV-1 drug-resistant virus."}